Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

141. Occupational challenges of physicians involved in tuberculosis control in China: a qualitative study. (Abstract)

Occupational challenges of physicians involved in tuberculosis control in China: a qualitative study.

2016 Lancet

142. Identification of populations at high risk of tuberculosis infection in rural China: a population-based, multicentre, prospective study. Full Text available with Trip Pro

Identification of populations at high risk of tuberculosis infection in rural China: a population-based, multicentre, prospective study.

2016 Lancet

143. Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults Full Text available with Trip Pro

Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults Systematic screening is often proposed as a way to improve case finding for tuberculosis (TB), but the cost-effectiveness of specific strategies for systematic screening remains poorly studied.We constructed a Markov-based decision analytic model to analyse the cost-effectiveness of triage testing for TB in Uganda, compared against passive case detection with Xpert MTB/RIF. We

2016 BMJ global health

144. Hematological and liver toxicity of anti-tuberculosis drugs Full Text available with Trip Pro

Hematological and liver toxicity of anti-tuberculosis drugs Tuberculosis (TB) is a major global health problem, and anti-tuberculosis drugs can cause severe adverse reactions. The aim of this study was to determine hematological and biochemical changes and associated risk factors in smear positive pulmonary tuberculosis patients undergoing treatment with standard protocols.In a descriptive study, a total of 40 tuberculosis patients aged between 15-60 years were collected from hospitals (...) , HCT, MCV, MCH, and MCHC), except platelet count, were changed significantly (p ≤ 0.001). Liver enzyme activities (ALT, AST, and ALP) were decreased significantly (p ≤ 0.001) after treatment.In this study, changes of hematological and biochemical parameters have been observed in patients with pulmonary tuberculosis. It can be concluded that the anti-tuberculosis treatment is associated with changes of hematological parameters and liver enzymes.

2016 Electronic physician

145. GenoType<sup>®</sup> MTBDRsl assay for resistance to second-line anti-tuberculosis drugs. Full Text available with Trip Pro

GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs. Genotype® MTBDRsl (MTBDRsl) is a rapid DNA-based test for detecting specific mutations associated with resistance to fluoroquinolones and second-line injectable drugs (SLIDs) in Mycobacterium tuberculosis complex. MTBDRsl version 2.0 (released in 2015) identifies the mutations detected by version 1.0, as well as additional mutations. The test may be performed on a culture isolate or a patient specimen (...) , which eliminates delays associated with culture. Version 1.0 requires a smear-positive specimen, while version 2.0 may use a smear-positive or -negative specimen. We performed this updated review as part of a World Health Organization process to develop updated guidelines for using MTBDRsl.To assess and compare the diagnostic accuracy of MTBDRsl for: 1. fluoroquinolone resistance, 2. SLID resistance, and 3. extensively drug-resistant tuberculosis, indirectly on a M. tuberculosis isolate grown from

2016 Cochrane

146. Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. Tuberculosis remains an important preventable disease in the United States. An effective strategy for reducing the transmission, morbidity, and mortality of active disease is the identification and treatment of latent tuberculosis infection (LTBI) to prevent progression to active disease.To issue a current US Preventive Services Task Force (USPSTF) recommendation on screening

2016 JAMA

147. Chronic heel pain: It could be tuberculosis Full Text available with Trip Pro

Chronic heel pain: It could be tuberculosis Heel pain is a common presentation at a primary care setting. The majority of these cases are benign and self limiting in nature. Common differential diagnoses include plantar fasciitis and peroneal muscle sprains. However, certain conditions-if undetected early-may cause significant morbidity to the patient. A high index of suspicion and early referral for further investigations are needed to prevent long-term morbidities.A clinical review (...) of a patient with chronic left heel pain was performed. Blood parameters and imaging investigations indicated chronic infection of the calcaneum. Histopathological examination was highly suggestive of tuberculosis.The patient responded well to antituberculous therapy. She was pain free and showed no signs of recurrence at final follow-up.Here, we report a case of chronic heel pain, which was later diagnosed as tuberculosis of the calcaneum and successfully treated with antituberculous therapy.

2016 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

148. Head and neck tuberculosis: The great mimic Full Text available with Trip Pro

Head and neck tuberculosis: The great mimic 28461859 2018 11 13 1985-207X 11 2-3 2016 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia Malays Fam Physician Head and neck tuberculosis: The great mimic. 38 Mohamad I I MD, M.Med (ORL-HNS), School of Medical Sciences, Universiti Sains Malaysia Health Campus, Kelantan, Malaysia, email:irfankb@usm.my. Nik Hassan Nfh N MD, M.Med (ORL-HNS), School of Health Sciences, Universiti Sains Malaysia Health (...) Campus, Kelantan, Malaysia. Nik Othman N A NA MBChB, M.Med (ORL-HNS), School of Health Sciences, Universiti Sains Malaysia Health Campus, Kelantan, Malaysia. eng Journal Article 2016 08 31 Malaysia Malays Fam Physician 101466855 1985-2274 Otolaryngology Tuberculosis Tuberculosis vaccines 2017 5 3 6 0 2017 5 4 6 0 2017 5 4 6 1 epublish 28461859 PMC5408878 J Laryngol Otol. 2009 Jul;123(7):764-7 18845038 Hum Vaccin Immunother. 2013 Aug;9(8):1763-73 23584253 Acta Med Indones. 2006 Jan-Mar;38(1):29-32

2016 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

149. HIV and tuberculosis in prisons in sub-Saharan Africa. Full Text available with Trip Pro

HIV and tuberculosis in prisons in sub-Saharan Africa. Given the dual epidemics of HIV and tuberculosis in sub-Saharan Africa and evidence suggesting a disproportionate burden of these diseases among detainees in the region, we aimed to investigate the epidemiology of HIV and tuberculosis in prison populations, describe services available and challenges to service delivery, and identify priority areas for programmatically relevant research in sub-Saharan African prisons. To this end, we (...) reviewed literature on HIV and tuberculosis in sub-Saharan African prisons published between 2011 and 2015, and identified data from only 24 of the 49 countries in the region. Where data were available, they were frequently of poor quality and rarely nationally representative. Prevalence of HIV infection ranged from 2·3% to 34·9%, and of tuberculosis from 0·4 to 16·3%; detainees nearly always had a higher prevalence of both diseases than did the non-incarcerated population in the same country. We

2016 Lancet

150. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. Full Text available with Trip Pro

Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. The burden of HIV/AIDS and other transmissible diseases is higher in prison and jail settings than in the non-incarcerated communities that surround them. In this comprehensive review, we discuss available literature on the topic of clinical management of people infected with HIV, hepatitis B and C viruses, and tuberculosis in incarcerated settings in addition to co-occurrence of one or more of these infections

2016 Lancet

151. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Full Text available with Trip Pro

Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The prison setting presents not only challenges, but also opportunities, for the prevention and treatment of HIV, viral hepatitis, and tuberculosis. We did a comprehensive literature search of data published between 2005 and 2015 to understand the global epidemiology of HIV, hepatitis C virus (HCV), hepatitis B virus (HBV), and tuberculosis in prisoners. We further modelled the contribution of imprisonment (...) and the potential impact of prevention interventions on HIV transmission in this population. Of the estimated 10·2 million people incarcerated worldwide on any given day in 2014, we estimated that 3·8% have HIV (389 000 living with HIV), 15·1% have HCV (1 546 500), 4·8% have chronic HBV (491 500), and 2·8% have active tuberculosis (286 000). The few studies on incidence suggest that intraprison transmission is generally low, except for large-scale outbreaks. Our model indicates that decreasing the incarceration

2016 Lancet

152. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Full Text available with Trip Pro

The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Despite global reductions in HIV incidence and mortality, the 15 UNAIDS-designated countries of Eastern Europe and Central Asia (EECA) that gained independence from the Soviet Union in 1991 constitute the only region where both continue to rise. HIV transmission in EECA is fuelled primarily by injection of opioids, with harsh (...) criminalisation of drug use that has resulted in extraordinarily high levels of incarceration. Consequently, people who inject drugs, including those with HIV, hepatitis C virus, and tuberculosis, are concentrated within prisons. Evidence-based primary and secondary prevention of HIV using opioid agonist therapies such as methadone and buprenorphine is available in prisons in only a handful of EECA countries (methadone or buprenorphine in five countries and needle and syringe programmes in three countries

2016 Lancet

153. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. (Abstract)

Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. The prevalence of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis are higher in prisons than in the general population in most countries worldwide. Prisons have emerged as a risk environment for these infections to be further concentrated, amplified, and then transmitted to the community after prisoners are released. In the absence of alternatives to incarceration, prisons

2016 Lancet

154. β-Lactams against Tuberculosis - New Trick for an Old Dog? Full Text available with Trip Pro

β-Lactams against Tuberculosis - New Trick for an Old Dog? 27433841 2016 08 05 2016 07 28 1533-4406 375 4 2016 Jul 28 The New England journal of medicine N. Engl. J. Med. β-Lactams against Tuberculosis--New Trick for an Old Dog? 393-4 10.1056/NEJMc1513236 Diacon Andreas H AH Stellenbosch University, Cape Town, South Africa ahd@sun.ac.za. van der Merwe Lize L Task Applied Science, Cape Town, South Africa. Barnard Marinus M Task Applied Science, Cape Town, South Africa. von Groote-Bidlingmaier (...) Agents 0 beta-Lactamase Inhibitors 0 beta-Lactams 74469-00-4 Amoxicillin-Potassium Clavulanate Combination AIM IM Amoxicillin-Potassium Clavulanate Combination therapeutic use Antitubercular Agents therapeutic use Colony Count, Microbial Drug Discovery Humans Mycobacterium tuberculosis Tuberculosis, Multidrug-Resistant drug therapy beta-Lactamase Inhibitors therapeutic use beta-Lactams therapeutic use 2016 7 20 6 0 2016 7 20 6 0 2016 8 6 6 0 ppublish 27433841 10.1056/NEJMc1513236

2016 NEJM

155. Tuberculosis and AIDS: major progress

Tuberculosis and AIDS: major progress Prescrire IN ENGLISH - Spotlight ''Tuberculosis and AIDS: major progress'', 1 July 2016 {1} {1} {1} | | > > > Tuberculosis and AIDS: major progress Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Tuberculosis and AIDS: major progress AIDS and tuberculosis still rank among the leading causes of death worldwide

2016 Prescrire

156. Baeyer-Villager monooxygenases EthA and MymA are required for activation of inhibitors against replicating and non-replicating Mycobacterium tuberculosis Full Text available with Trip Pro

Baeyer-Villager monooxygenases EthA and MymA are required for activation of inhibitors against replicating and non-replicating Mycobacterium tuberculosis Successful treatment of Mycobacterium tuberculosis infection typically requires a complex regimen administered over at least 6 months. Interestingly, many of the antibiotics used to treat M. tuberculosis are prodrugs that require intracellular activation. Here, we describe three small molecules, active against both replicating and non (...) -replicating M. tuberculosis, that require activation by Baeyer-Villiger monooxygenases (BVMOs). Two molecules require BVMO EthA (Rv3854c) for activation and the third molecule requires the BVMO MymA (Rv3083). While EthA is known to activate the antitubercular drug ethionamide, this is the first description of MymA as an activating enzyme of a prodrug. Furthermore, we found that MymA also plays a role in activating ethionamide, with loss of MymA function resulting in ethionamide-resistant M. tuberculosis

2016 Cell chemical biology

157. Misdiagnosis of Cancer as Tuberculosis in Low- to Middle-Income Countries: A Tip of the Iceberg! Full Text available with Trip Pro

Misdiagnosis of Cancer as Tuberculosis in Low- to Middle-Income Countries: A Tip of the Iceberg! 28717707 2019 01 13 2378-9506 2 4 2016 Aug Journal of global oncology J Glob Oncol Misdiagnosis of Cancer as Tuberculosis in Low- to Middle-Income Countries: A Tip of the Iceberg! 244-245 10.1200/JGO.2016.004457 Hannan Abdul A East Tennessee State University, Johnson City, TN. eng Journal Article 2016 05 18 United States J Glob Oncol 101674751 2378-9506 The following represents disclosure

2016 Journal of global oncology

158. OsdR of Streptomyces coelicolor and the Dormancy Regulator DevR of Mycobacterium tuberculosis Control Overlapping Regulons Full Text available with Trip Pro

OsdR of Streptomyces coelicolor and the Dormancy Regulator DevR of Mycobacterium tuberculosis Control Overlapping Regulons Two-component regulatory systems allow bacteria to respond adequately to changes in their environment. In response to a given stimulus, a sensory kinase activates its cognate response regulator via reversible phosphorylation. The response regulator DevR activates a state of dormancy under hypoxia in Mycobacterium tuberculosis, allowing this pathogen to escape the host (...) defense system. Here, we show that OsdR (SCO0204) of the soil bacterium Streptomyces coelicolor is a functional orthologue of DevR. OsdR, when activated by the sensory kinase OsdK (SCO0203), binds upstream of the DevR-controlled dormancy genes devR, hspX, and Rv3134c of M. tuberculosis. In silico analysis of the S. coelicolor genome combined with in vitro DNA binding studies identified many binding sites in the genomic region around osdR itself and upstream of stress-related genes. This binding

2016 mSystems

159. Immune reconstitution inflammatory syndrome in a HIV-infected patient with disseminated tuberculosis Full Text available with Trip Pro

Immune reconstitution inflammatory syndrome in a HIV-infected patient with disseminated tuberculosis Immune reconstitution inflammatory syndrome (IRIS) is the paradoxical worsening of pre-existing infectious processes after commencement of anti-retroviral therapy (ART) in HIV-infected patients. Its manifestations are dependent on the underlying opportunistic infections. We report a case of an HIV-infected patient with disseminated tuberculosis, who responded to anti-tuberculosis therapy

2016 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

160. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Full Text available with Trip Pro

A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Identification of blood biomarkers that prospectively predict progression of Mycobacterium tuberculosis infection to tuberculosis disease might lead to interventions that combat the tuberculosis epidemic. We aimed to assess whether global gene expression measured in whole blood of healthy people allowed identification of prospective signatures of risk of active tuberculosis disease.In this prospective cohort study (...) , we followed up healthy, South African adolescents aged 12-18 years from the adolescent cohort study (ACS) who were infected with M tuberculosis for 2 years. We collected blood samples from study participants every 6 months and monitored the adolescents for progression to tuberculosis disease. A prospective signature of risk was derived from whole blood RNA sequencing data by comparing participants who developed active tuberculosis disease (progressors) with those who remained healthy (matched

2016 Lancet